Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Sjoukje F. Oosting"'
Autor:
Manouk K. Bos, Sarah R. Verhoeff, Sjoukje F. Oosting, Willemien C. Menke-van der Houven van Oordt, Ruben G. Boers, Joachim B. Boers, Joost Gribnau, John W. M. Martens, Stefan Sleijfer, Carla M. L. van Herpen, Saskia M. Wilting
Publikováno v:
Cancers, Vol 15, Iss 5, p 1374 (2023)
According to the current guidelines, watchful waiting (WW) is a feasible option for patients with good or intermediate prognosis renal-cell carcinoma (RCC). However, some patients rapidly progress during WW, requiring the initiation of treatment. Her
Externí odkaz:
https://doaj.org/article/cbabc4b832614067b0099dc4352b4ac8
Autor:
Saskia H. Hanemaaijer, Iris C. Kok, Rudolf S. N. Fehrmann, Bert van der Vegt, Jourik A. Gietema, Boudewijn E. C. Plaat, Marcel A. T. M. van Vugt, Marije R. Vergeer, C. René Leemans, Johannes A. Langendijk, Jens Voortman, Jan Buter, Sjoukje F. Oosting
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). However, around one-third of the patients cannot complete cisplatin beca
Externí odkaz:
https://doaj.org/article/41c85e17066d44cbaa8705b2b5208976
Autor:
Sjoukje F. Oosting, Robert I. Haddad
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Treating head and neck cancer patients with systemic therapy is challenging because of tumor related, patient related and treatment related factors. In this review, we aim to summarize the current standard of care in the curative and palliative setti
Externí odkaz:
https://doaj.org/article/b33acc77a17341a5b9f64781afef264f
Autor:
Elisabeth GE de Vries, Marjolijn N Lub-de Hooge, Sjoukje F Oosting, Pim P van de Donk, Daan G Knapen, Anthonie J van der Wekken, Adrienne H Brouwers, Derk-Jan A de Groot
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patient
Externí odkaz:
https://doaj.org/article/1c4117e2a0ec420c864e6d697316ea5b
Autor:
Martin H. Voss, Arun A. Azad, Aaron R. Hansen, Jhanelle E. Gray, Sarah J. Welsh, Xuyang Song, Michael Kuziora, Lina Meinecke, Jorge Blando, Ikbel Achour, Yi Wang, Farzana L. Walcott, Sjoukje F. Oosting
Publikováno v:
Clinical Cancer Research. 28:3032-3041
Purpose: MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated an
Autor:
Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff
Score chart with predicted probability (%) to remain on WW at 12 months This model was based on the number of IMDC Risk factors (0, 1, 2), the number or involved organ sites (0 - 4) and the geometric mean [¹⁸F]FDG SUVmax as a continuous variable.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024dde545016efb5249512402f68978b
https://doi.org/10.1158/1078-0432.22489029
https://doi.org/10.1158/1078-0432.22489029
Autor:
Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff
Lasso model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a247ec4ea06246a4709494c1fa5dbaa5
https://doi.org/10.1158/1078-0432.22489035
https://doi.org/10.1158/1078-0432.22489035
Autor:
Carla M.L. van Herpen, Wim J.G. Oyen, Erik H.J.G. Aarntzen, Winette T.A. van der Graaf, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Peter F.A. Mulders, Bertha Eisses, Adrienne H. Brouwers, Anne I.J. Arens, Astrid A.M. van der Veldt, C. Willemien Menke-van der Houven van Oordt, Ingrid M.E. Desar, Sandra Heskamp, Lindsay Angus, Sophie L. Gerritse, Suzanne C. van Es, Sjoerd G. Elias, Sjoukje F. Oosting, Sarah R. Verhoeff
Purpose:Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with 18F]FDG PET/CT and [89Zr]Zr-DFO-girentuximab PET/CT for WW duration in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0d98d95deb14bae81ed33d1c0ff2717
https://doi.org/10.1158/1078-0432.c.6532866
https://doi.org/10.1158/1078-0432.c.6532866
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fba7a4c3002c9cc8f82b28dcf07d21
https://doi.org/10.1158/1078-0432.22487043
https://doi.org/10.1158/1078-0432.22487043
Autor:
Sjoukje F. Oosting, Farzana L. Walcott, Yi Wang, Ikbel Achour, Jorge Blando, Lina Meinecke, Michael Kuziora, Xuyang Song, Sarah J. Welsh, Jhanelle E. Gray, Aaron R. Hansen, Arun A. Azad, Martin H. Voss
Purpose:MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a90975dd8fcf92fc4c41ce20296e40
https://doi.org/10.1158/1078-0432.c.6532443.v1
https://doi.org/10.1158/1078-0432.c.6532443.v1